Simulated results indicated continued tumor growth under lapatinib alone but significantly reduced growth when we decrease the activation rate of PI3K (mimicking the effect of PI3K inhibitor) (Fig. 7i), and this is consistent with the experimental findings from a HCC1954 cell xenograft model with endogenous PIK3CA mutation [77]. The gene discussed is PIK3CA; the disease is neoplasm.